Production (Stage)
Capricor Therapeutics, Inc.
CAPR
$12.38
$0.605.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -7.92% | -63.44% | 1.38% | 64.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -7.92% | -63.44% | 1.38% | 64.29% |
| Cost of Revenue | 70.40% | 46.42% | 17.74% | 41.82% | 44.89% |
| Gross Profit | -205.38% | -259.43% | -148.39% | -74.15% | -32.50% |
| SG&A Expenses | 49.01% | 24.62% | 14.64% | 7.40% | 16.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.66% | 40.83% | 17.02% | 33.42% | 35.82% |
| Operating Income | -143.36% | -500.78% | -89.52% | -49.62% | -25.43% |
| Income Before Tax | -149.04% | -833.81% | -96.49% | -49.32% | -26.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -149.04% | -833.81% | -96.49% | -49.32% | -26.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -149.04% | -833.81% | -96.49% | -49.32% | -26.08% |
| EBIT | -143.36% | -500.78% | -89.52% | -49.62% | -25.43% |
| EBITDA | -147.40% | -651.99% | -91.99% | -49.94% | -24.89% |
| EPS Basic | -71.09% | -542.17% | -53.33% | -18.78% | -1.53% |
| Normalized Basic EPS | -70.08% | -534.19% | -53.43% | -18.82% | -1.51% |
| EPS Diluted | -71.09% | -542.17% | -53.33% | -18.78% | -1.53% |
| Normalized Diluted EPS | -70.08% | -534.19% | -53.43% | -18.82% | -1.51% |
| Average Basic Shares Outstanding | 45.55% | 45.15% | 28.17% | 25.68% | 24.19% |
| Average Diluted Shares Outstanding | 45.55% | 45.15% | 28.17% | 25.68% | 24.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |